Phase ia study of the indoleamine 2,3-dioxygenase 1 (ido1) inhibitor navoximod (gdc-0919) in patients with recurrent advanced solid tumors

HIGHLIGHTS

• who: Asha Nayak-Kapoor from the Georgia Cancer Center at Augusta University, Augusta, GA, USA have published the article: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors, in the Journal: (JOURNAL) of Nov/16,/2016
• what: The aims of this study were to evaluate the safety and tolerability of single-agent navoximod and to determine the maximum tolerated dose (MTD) in patients with recurrent advanced solid tumors. In this study, none of the AEs were reported as immune-related; however, 1 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.